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Splanchnic vein thrombosis in myeloproliferative neoplasms:
risk factors for recurrences in a cohort of 181 patients
V De Stefano1,25, AM Vannucchi2,25, M Ruggeri3, F Cervantes4, A Alvarez-Larrán5, A Iurlo6, ML Randi7, L Pieri2, E Rossi1, P Guglielmelli2,
S Betti1, E Elli8, MC Finazzi9, G Finazzi9, E Zetterberg10, N Vianelli11, G Gaidano12, I Nichele3, D Cattaneo6, M Palova13, MH Ellis14,
E Cacciola15, A Tieghi16, JC Hernandez-Boluda17, E Pungolino18, G Specchia19, D Rapezzi20, A Forcina21, C Musolino22, A Carobbio23,
M Griesshammer24 and T Barbui23,25
We retrospectively studied 181 patients with polycythaemia vera (n= 67), essential thrombocythaemia (n= 67) or primary
myelofibrosis (n= 47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd–Chiari syndrome (BCS) and portal
vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or
splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient
years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated
with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62),
splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and
the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per
100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the
corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in
myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new
antithrombotic drugs and JAK-2 inhibitors.
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INTRODUCTION
Splanchnic vein thrombosis (SVT) encompasses hepatic veins
(Budd–Chiari syndrome, BCS) and portal, mesenteric and splenic
veins, and is a rare event in the general population: the annual
incidence accounts for 0.8 per million for BCS, 0.7 per 100 000 for
portal vein thrombosis and 2.7 per 100 000 for mesenteric vein
thrombosis.1–4 In these cases, the JAK2V617F mutation, the
hallmark of myeloproliferative neoplasms (MPNs), can be detected
in 13.6–26.6% of non-cirrhotic and non-malignant SVT patients,
even in the absence of a clear diagnostic picture of MPN.5 In fully
expressed Philadelphia-negative MPN, including polycythaemia
vera (PV), essential thrombocythaemia and primary myelofibrosis,
the more frequent sites of thrombosis are arterial vessels or leg veins
and pulmonary embolisms (PEs) but also include unusual sites such
as cerebral veins6 and SVT. These latter occur at much higher
frequency (1–10%)7 than in the general population, where the
incidence of these rare events is no more than 2–3 per 100 000.1–4
Whether the recurrent events have a higher frequency than in
the non-MPN population has not yet been assessed in a large
series of patients with a well-established diagnosis of fully
expressed MPN. To prevent recurrence, there is a general
consensus that vitamin K-antagonist (VKA) should be prescribed
long-term, very often in combination with cytoreductive
therapy.8,9 However, this recommendation is based on a
consensus among the experts and is not universally accepted. A
recent survey involving expert haematologists revealed a marked
heterogeneity of choices on the duration of VKA and on the use of
cytoreduction; moreover, this survey showed great uncer-
tainty regarding the use of aspirin either alone or in association
with VKA.10
In this study, we retrospectively collected a cohort of 181
SVT index events occurring in strictly defined patients with
PV, essential thrombocythaemia and primary myelofibrosis
managed in the clinical practice of 23 haematologic
European centres. We describe here the pattern of presentation
and the rate and risk factors of recurrent thrombotic events, and
report the bleeding associated with secondary prophylaxis
therapy.
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PATIENTS AND METHODS
Study patients
A retrospective study was conducted across 23 centres within the
European Leukaemia Network on patients with a diagnosis of MPN
according to the World Health Organization 2008 criteria,11 after the
approval of the ethics committees (primary approval by the central ethics
committees of the coordinating centre was obtained on 2 October 2014).
The participating centres were asked to select from their consecutive
patients with MPN, the ones who had had venous thromboembolism (VTE)
objectively documented from January 2005, including deep venous
thrombosis (DVT) of the limbs, PE, thrombosis of the cerebral and
splanchnic veins (hepatic, portal, mesenteric and splenic veins) and
thrombosis of the retinal vein, and who had received a course of VKA or
direct oral anticoagulants. The data were collected in an electronic system.
Each centre reported the total number of medical files by data input into
an electronic database developed to record all study data; patients were
de-identified with an alphanumeric code to protect personal privacy.
The details of the survey procedure and the results obtained in the
patients with DVT of the legs and/or PE have been previously published.12
Briefly, for each patient, the following information was recorded:
demographic data, WHO diagnosis, location of thrombosis, method of
objective diagnosis, the presence of microvascular disturbances (that is,
erythromelalgia, transient ocular attacks, pulsatile headache, dizziness and
tinnitus) or constitutional symptoms (that is, pruritus, fatigue, night sweats,
fever, weight loss and pain in the limbs), mutational profile, results of the
laboratory investigation for thrombophilia, full blood count at diagnosis
and at thrombosis, and the presence of cardiovascular risk factors (that is,
history of previous thrombosis before the index event, smoking habit,
hypertension, dyslipidaemia and diabetes). Moreover, the presence of
circumstantial risk factors at the time of any episode of VTE such as
surgery, pregnancy, puerperium (until 6 weeks from delivery), oral
contraceptive intake, hormone replacement therapy, trauma, leg cast,
prolonged bed immobilization (410 days) and long travel (48 h) was also
recorded; in the absence of the previously mentioned risk factors, VTE was
considered unprovoked. Finally, the data regarding cytoreductive or
antithrombotic treatment after VTE, the duration of the treatment and the
reasons for discontinuation of the treatment was recorded. A diagnosis of
VTE was accepted only if it was confirmed by objective methods according
to current clinical practice, as previously reported,12 and was defined as a
positive result using techniques such as angiography, ultrasonography,
computerized tomography or nuclear magnetic resonance.
Outcomes
The aim of this study was to determine the rate of recurrent thrombosis in
patients recruited in the general database, who had an SVT as an index
event. SVT was defined as thrombosis of the hepatic, portal, mesenteric
and splenic veins.
Venous or arterial thrombotic events that occurred after the index event
were recorded only if objectively documented. Recurrent SVT was defined
as an objectively established thrombus extension or occurrence in a
previously patent segment, as previously defined.13 The following new
manifestations, when objectively proven, were also defined as recurrent
VTE: DVT of the arms or the limbs, PE and occlusion of cerebral veins.
Finally, new arterial thrombotic events included ischaemic stroke, transient
ischaemic attack, acute myocardial infarction, unstable angina pectoris and
peripheral arterial thrombosis, when objectively diagnosed, as previously
reported.12–14
Major bleeding was defined according to the criteria of the International
Society on Thrombosis and Haemostasis15 when it was fatal and/or was
symptomatic in a critical area or organ, such as intracranial bleeding,
intraspinal bleeding, intraocular bleeding, retroperitoneal bleeding, intra-
articular bleeding, pericardial bleeding, intramuscular bleeding with
compartment syndrome and/or bleeding that led to a reduction of
2 g/dl or more in the haemoglobin concentration and/or necessitated the
transfusion of two or more blood units.
Statistical methods
For continuous variables, the median and the range are provided. The
annual incidence of recurrent thrombosis was calculated by dividing the
number of events by the total number of patient years (pt-years).
Differences in the proportions were estimated using the Fisher’s exact test
(statistical significance threshold set at Po0.05).
A multivariable model, including age 460 years, thrombosis history,
cardiovascular risk factors, Hb415 g/dl, Hct445%, white blood cell (WBC)
count414× 109/l, platelet count4500× 109/l, splenomegaly, unprovoked
event, BCS as index event versus other SVT index events, VKA treatment
and other treatments, was performed to identify the significant predictors
of recurrence or bleeding. Starting with all candidate variables, backward
selection was used to test whether the deletion or retention of each
variable improved the model, repeating this process until no further
improvement was possible.
The probability of recurrence as a function of time was estimated using
the Kaplan–Meier method by analysing the interval between the index
thrombosis and a recurrent thrombotic event (uncensored observations) or
the duration of time until death, or the time elapsed until the patient’s final
visit to the centre (censored observations). The thrombosis recurrence-free
survival was compared between the groups using the log-rank test
(statistical significance threshold set at Po0.05) and the relative risk of
recurrence was estimated as a hazard ratio (HR) with a 95% confidence
interval using a Cox proportional hazard regression model.
RESULTS
Clinical and laboratory features of the patient cohort
Overall, 181 patients with SVT at MPN diagnosis (58%) or during
the course of the disease were recruited (Table 1). The female sex
was prevalent (65.2%); at the time of the index event, only a
minority of patients (22.1%) were over 60 years of age and 28.2%
were under 40 years of age.
BCS and portal vein thrombosis were observed in 31 (17.1%)
and 109 (60.3%) patients, respectively. The remaining 41 patients
presented with isolated thrombosis of the mesenteric or splenic
veins. The great majority were splenomegalic (median 4 cm below
the costal margin) and one quarter reported microvascular
disturbances and constitutional symptoms. Almost all (93.3%)
carried the JAK2V617F mutation and 35% tested positive for
genetic or acquired thrombophilia. No risk circumstance provok-
ing SVT was present in the majority of the patients (85.6%). Of
note, 113 patients (62.4%) had elevated blood counts, defined as
Hct 445% and/or WBC414 × 109/l and/or platelet count
4500× 109/l; no patient had WBC and platelet counts lower than
3.0 × 109 and 100 × 109/l, respectively.
Incidence of new vascular events after the index event and risk
factors
All patients received a course of low-molecular-weight heparin as
initial therapy, followed in the majority of the patients by VKA
(153/181, 84.5%) as secondary prophylaxis (Table 2). Among
patients on VKA, the drug was continued indefinitely in 136
(88.9%) for a median follow-up time of 3.5 years (range 8 months–
15.8 years) and was discontinued in 17 (9.3%) after a median time
of 2 years (range 1 month–6.2 years). The reasons for stopping
VKA included a pre-established plan by the centres in six cases
and major bleeding in three; in the remaining patients, VKA was
discontinued because of the patient’s preference or bleeding risk
judged to be excessive by the care physician (for example, onset
of thrombocytopenia during the course of the disease).
The overall observation time recorded after the SVT index event
was 735 years (median 3.2, range 1 month to 15.8 years). There
were 31 new episodes of thrombosis in 31 patients, with an overall
incidence rate (IR) of 4.2 per 100 pt-years (95% confidence interval
(95% CI): 2.9–5.9); 17 thrombotic events (54.8%) occurred within 2
years from the date of the index SVT. Sites of events were in the
splanchnic veins in 45% and at other sites in 55%: cerebral veins,
venous legs with or without PE and arterial occlusions (Table 3).
No significant differences were found between the patients
who had a recurrence and those who did not regarding diagnosis
of PV (P= 0.15), essential thrombocythaemia (P= 0.41) and MF
(P= 0.82), the presence of JAK2V617F mutation (P= 0.69) and
thrombophilia (P= 0.13).
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Backward logistic regression analysis showed an independent
association with the new thrombotic event for BCS (HR: 3.03, 95%
CI: 1.37–6.69), history of previous thrombosis (HR: 3.62, 95%
CI: 1.22–10.78), splenomegaly (HR: 2.66, 95% CI: 1.06–6.64) and
leukocytosis higher than the highest quartile, 14 × 109/l (HR: 2.8,
95% CI: 1.32–6.28). In particular, patients with BCS had an
incidence rate of new events of 8.0 per 100 pt-years (95% CI:
4.0–14.4) that was significantly higher than in those with
thrombosis of portal or other abdominal sites (Table 4). This
difference was due to an increased rate of venous events in BCS
patients, whereas no difference between the two groups was
noticed in the rate of new arterial thromboses; of note, in patients
with BCS there was a threefold increase in risk of recurrent SVT in
respect to that of patients with other index SVT (5/31, 16.1%
versus 9/150, 6%, odds ratio: 3.01, 95% CI: 0.93–9.71, P= 0.06). The
time to new events according to the presence of such risk factors
is shown in the Kaplan–Meier curves of Figures 1 and 2.
Effect of VKA antithrombotic treatment on the incidence of
recurrent thrombosis
Patients on VKA (n= 136) experienced 23 new thrombotic events
during a follow-up of 585 years, corresponding to a rate of 3.9
(95% CI: 2.4–5.8) per 100 pt-years. Fourteen events (60.8%)
involved venous vesselsnine recurrent SVT, two DVT of the legs,
two PE and one cerebral vein thrombosis. The remaining events
were ischaemic stroke (n= 3), acute coronary syndrome (n= 2),
peripheral artery thrombosis (n= 2) and retinal artery thrombosis
(n= 1); the site of one event was not specified. In 13 cases, the
international normalized ratio value at the time of recurrence was
available, being within the therapeutic range 2.0–3.0 in six cases
(range 2.10–2.80), o2.0 in five cases (range 1.70–1.85) and 43.0
in two cases (range 5.03–7.10).
Patients who discontinued VKA (n= 17) and patients who never
received VKA or direct oral anticoagulant prophylaxis (n= 25) were
followed up for 146 years and developed 4 and 4 events,
respectively, corresponding to an overall annual rate of 5.4 (95%
CI: 2.3–10.7) per 100 pt-years, which was not significantly different
from that observed in patients receiving VKA (P= 0.41). Five events
(62.5%) were recurrent SVT. The remaining events were myocar-
dial infarction (n= 1) and peripheral artery thrombosis (n= 1); the
site of one event was not specified.
The comparison between the patients with ongoing VKA and
those off VKA at the time of recruitment in the survey was
repeated by analysis on-treatment. Among the patients who
received VKA after the index event for a limited period of time, the
total observation time was 36 pt-years on VKA; therefore,
the overall pt-years on VKA and off VKA were 621 and 110,
respectively. Accordingly, the rate of recurrences per 100
pt-years with or without VKA was 3.7 (95% CI: 2.3–5.5) and 7.2
(95% CI: 3.1–14.3), respectively (P= 0.09). The 4 pt-years attributed
to the three patients on direct oral anticoagulants were not
computed in the analysis; none of these latter patients had a
recurrent thrombosis.
Table 1. Clinical features of the cohort at the time of the index event
Male/female, N (%) 63/118 (34.8/65.2)
Age, years, median (range) 48 (29–74)
o40 years, n (%) 51 (28.2)
40–60 years, n (%) 90 (49.7)
⩾ 60 years, n (%) 40 (22.1)
Diagnosis, N (%)
PV 67 (37.0)
ET 67 (37.0)
PMF 47 (26.0)
Years from diagnosis to index thrombosis,
mean (± s.d.)
2.01 (3.87)
Diagnosis at the time of index thrombosis,
n (%)
105 (58)
Hb gr/dl, median (range) 13.4 (6.3–24.0)
Hct %, median (range) 42.1 (22.0–70.0)
WBC count ×109/l, median (range) 9.3 (3.0–50.0)
Platelet count × 109/l, median (range) 424 (100–3000)
JAK2 mutation, N/N tested (%) 166/178 (93.3)
CALR mutations, N/N tested 4/25 (16.0)
MPL mutations, N/N tested 1/28 (3.6)
Exon 12 mutations, N/N tested 0/14 (0.0)
Abnormal karyotype, N/N tested (%) 8/65 (12.3)
Microvascular disturbances, N (%) 19 (10.5)
Constitutional symptoms, N (%) 28 (15.5)
Palpable splenomegaly, N (%) 119 (65.8)
Cm below costal margin, median (range) 4 (1–25)
Localization of index thrombosis, N (%)
Hepatic vein thrombosis (BCS) 31 (17.1)
Portal vein thrombosis 109 (60.3)
Mesenteric vein thrombosis 18 (9.9)
Splenic vein thrombosis 23 (12.7)
Unprovoked thrombosis, N (%) 155 (85.6)
Provoked by, n (%) 26 (14.4)
Oral contraceptives 8 (4.4)
Hormone replacement therapy 3 (1.7)
Infection 3 (1.7)
Pregnancy/puerperium 1 (0.6)
Cancer 1 (0.6)
Surgery 7 (3.9)
Liver disease 3 (1.7)
Risk factors for index thrombosis
History of thrombosis, N (%) 14 (7.7)
History of arterial thrombosis, n (%) 5 (2.8)
History of venous thrombosis, n (%) 8 (4.4)
Presence of at least one vascular risk factor,
N (%)
52 (28.7)
Smoking habit 19 (10.5)
Hypertension 28 (15.5)
Dislipidemia 7 (3.4)
Diabetes 5 (2.8)
Presence of thrombophilia*, N/N tested (%) 42/120 (35.0)
Inherited thrombophilia, N/N tested (%) 21/120 (17.5)
Abbreviations: BCS, Budd Chiari syndrome; ET, essential thrombocythae-
mia; Hb, haemoglobin; PMF, primary myelofibrosis; PV, polycythaemia vera;
WBC, white blood cell. Deficiency of antitrombin (n= 1), deficiency of
protein C or protein S (n= 7), factor V Leiden and/or prothrombin G20210A
(n= 13), increased levels of homocysteine (n= 16), antiphospholipids
(n= 6).
Table 2. Treatment after the index thrombosis
Total (%) Cytoreductiona
Yes No
VKA 143 (79.0) 101 (70.6) 42 (29.4)
VKA+antiplatelets 10 (5.5) 6 (60.0) 4 (40.0)
Antiplatelets 6 (3.3) 6 (100) 2 (0)
Heparin 10 (5.5) 7 (70.0) 3 (30.0)
DOACs 3 (1.7) 2 (66.7) 1 (33.3)
No antithrombotic treatment 9 (5.0) 8 (88.9) 1 (11.1)
Total (%) 181 (100) 130 (71.8) 51 (28.2)
Abbreviations: DOAC, direct oral anticoagulant; VKA, vitamin
K-antagonists. aHydroxyurea in 108/130 cases (83%).
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The rate of new thrombotic events in patients receiving
antiplatelet agents alone or in association with VKA (n= 16) was
4.3 (95% CI: 0.5–15.7) per 100 pt-years and the combination of
aspirin with VKA did not produce any advantage on the overall
rate of thrombosis (P= 0.79). However, all the arterial thrombotic
events occurred in the absence of antiplatelet agents.
Effect of cytoreductive treatment on the incidence of recurrent
thrombosis
Cytoreduction (mostly hydroxyurea) was administered to 130
patients (71.8% of the cohort) and was combined with VKA in 107
(82.3%). Patients with or without cytoreduction did not differ in
the rate of PV, essential thrombocythaemia or MF diagnosis, age
460 years, BCS as index event, Hb 415 g/dl, WBC count
414× 109/l, platelet count 4500× 109/l, splenomegaly and VKA
treatment (data not shown). In patients receiving cytoreduction 23
recurrent events were recorded over 537 pt-years (IR 4.2 per 100
pt-years, 95% CI: 2.7–6.4) and in patients without cytoreductive
treatment 8 recurrent events were recorded over 198 pt-years (IR
4.0 per 100 pt-years, 95% CI: 1.7–7.9; P= 0.94). The analysis of the
patients receiving both VKA and cytoreduction disclosed 20
recurrences over 471 pt-years (IR 4.2 per 100 pt-years, 95% CI: 2.5–
6.5). Finally, four patients received ruxolitinib and had no
recurrence after the SVT index event.
Overall, in patients not receiving cytoreduction after the index
event, Hb 415 g/dl and/or WBC count 414× 109/l, and/or a
platelet count 4500 × 109/l was recorded at the time of the
recurrent thrombosis in three of eight cases with recurrences
(37.5%). Similar blood values indicating a poor control of cell
proliferation were observed at the time of the recurrence in 14 of
the remaining 23 patients (60.8%) who had recurrent thrombosis
during cytoreduction.
Incidence rate of major bleeding
Major bleeding occurred in 16 patients, with a rate of 2.1 (95% CI:
1.3–3.5) per 100 pt-years and was intracranial in 4 cases (Table 3).
Thirteen events (81.2%) occurred in patients on VKA, one of which
was a fatal intracranial haemorrhage. Two bleeding events
occurred during treatment with ticlopidine; the remaining patient
was not receiving any antithrombotic treatment. The incidences of
major bleeding in patients taking and not taking VKA were 2.0
(95% CI: 1.1–3.5) and 2.7 (95% CI: 0.5–7.9) per 100 pt-years,
respectively (P= 0.67; on-treatment analysis).
A tendency towards a significantly higher IR of major bleeding
was recorded in patients receiving cytoreduction (2.7 per 100
pt-years, 95% CI: 1.5–4.6) in respect to those without cytoreductive
treatment (0.5 per 100 pt-years, 95% CI: 0.0–2.8; P= 0.06).
Development of haematological transformation and solid cancer
During the follow-up (median 3.2 years), the progression to overt
myelofibrosis and acute myeloid leukaemia was ascertained in 11
(6.1%) and 4 patients (2.2%), respectively; solid cancer was
recorded in 4 patients (2.2%; Table 3). The rate of haematological
transformation tended to be higher in patients who had SVT
during the follow-up after MPN diagnosis in comparison with
patients who had SVT at the MPN diagnosis (11.8% vs 5.7%,
P= 0.15).
The disease transformation was unrelated to recurrent throm-
botic events (odds ratio for transformation 1.8, 95% CI: 0.5–6.3,
P= 0.29).
DISCUSSION
Despite the large number of reports of retrospective or
prospective case series and meta-analyses concerning the
association between SVT and MPN,5 the studies on prophylaxis
after MPN-related SVT are limited to small series of no more than
50 patients.13,16–21 Our survey is the largest study cohort of MPN-
related SVT ever reported, describing in detail the treatments after
the index event, the subsequent outcomes and the risk factors for
recurrence.
SVT was the heralding manifestation of MPN in 58% of the
patients and followed the diagnosis of MPN in 42%; this result is
substantially aligned with the results of a meta-analysis in which
36% of the MPN-related SVT occurred during the follow-up after
diagnosis.22 The most frequent site of thrombosis was the portal-
mesenteric axis and BCS accounted for 17%; this latter frequency
is slightly higher than the value observed in the general
population, where BCS accounts for 5 to 12% of SVT.13,23,24 The
majority of patients were young females (65%), with a median age
of 48 years, in agreement with previous MPN series16,19,25 and
contrasting with the gender and older median age observed in
the general population.13,23
Table 3. Overall incidence of major outcomes after the index SVT
Events, n (%) Incidence rate per
100 pt-years (95% CI)
Thrombotic events 31 (17.1) 4.2 (2.9–5.9)
Venous thrombosis 19 (10.5) 2.5 (1.6–4.0)
Recurrent SVT 1.9 (1.1–3.1)
Hepatic vein thrombosis 3 (1.7)
Portal vein thrombosis 4 (2.2)
Mesenteric vein thrombosis 6 (3.1)
Splenic vein thrombosis 1 (0.6)
Venous thrombosis at other sites 0.6 (0.2–1.5)
DVT 2 (1.1)
PE 2 (1.1)
Cerebral vein thrombosis 1 (0.6)
Arterial thrombosis 10 (5.5) 1.3 (0.7–2.4)
Unstable angina 1 (0.6)
Myocardial infarction 2 (1.1)
Ischaemic stroke 3 (1.7)
Peripheral artery thrombosis 3 (1.7)
Retinal artery thrombosis 1 (0.6)
Not specified 2 (1.1)
Major bleeding 16 (8.8) 2.1 (1.3–3.5)
CNS 4 (2.2)
Gastrointestinal 6 (3.1)
Muscle hematoma 2 (1.1)
Unspecified 4 (2.2)
Hematologic evolutions 15 (8.3) 2.0 (1.2–3.3)
MF 11 (6.1)
AML 4 (2.2)
Solid cancer 4 (2.2) 0.5 (0.2–1.3)
Brain glioblastoma 1 (0.5)
Breast cancer 1 (0.5)
Nose skin cancer 1 (0.5
Pancreas cancer 1 (0.5)
Deaths 14 (7.7) 1.9 (1.1–3.1)
ICH 1 (0.6)
Infection 1 (0.6)
MF 1 (0.6)
AML 4 (2.2)
Solid tumour 2 (1.1)
Other 2 (1.1)
Unknown 3 (1.7)
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CNS,
central nervous system; DVT, deep vein thrombosis; ICH, intracranial
haemorrhage; MF, myelofibrosis; PE, pulmonary embolism; pt-years, patient
years; SVT, splanchnic vein thrombosis
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Inherited or acquired thrombophilia was found in one-third of
the evaluated patients, with no difference compared with the
diagnostic yield obtained in the general patient series.1,13,23 Of
note, almost all patients (93%) carried the JAK2 V617F mutation,
confirming the strength of association between this mutation and
vascular events.5,26
After a median follow-up of 3.2 years, 31 new throm-
boses were recorded, including both splanchnic and other
venous, as well as arterial occlusions. The overall incidence
rate of recurrent thrombosis was 4.2 per 100 pt-years,
which is consistent with the prospective incidence of
5.9 per 100 pt-years reported in a small series of MPN-related
SVT.13
Multivariable analysis revealed that BCS, history of thrombosis,
splenomegaly and leukocytosis were independently associated
with recurrence. The high incidence of recurrences in BCS was also
reported by others, both in MPN patients20,21 and in the non-MPN
population.23 A predictive role for incident thrombosis in prior
Table 4. Sub-analysis of major outcomes and type of SVT index event (BCS vs other SVT)
Index BCS (n=31) pt-years = 136 Other index SVT (n= 150) pt-years = 599 P-value
Thrombotic events, n (%) 11 (35.4) 20 (13.3) 0.006
Incidence rate, per 100 pt-years (95% CI) 8.0 (4.0–14.4) 3.3 (2.0–5.1) 0.01
Venous thrombosis, n (%) 7 (22.5) 12 (8.0) 0.02
Incidence rate, per 100 pt-years (95% CI) 5.1 (2.0–10.6) 2.0 (1.0–3.4) 0.03
Arterial thrombosis, n (%) 3 (9.6) 7 (4.6) 0.37
Incidence rate, per 100 pt-years (95% CI) 2.2 (0.4–6.4) 1.1 (0.4–2.4) 0.34
Major bleeding 3 (9.6) 13 (8.6 0.74
Incidence rate, per 100 pt-years (95% CI) 2.2 (0.4–6.4) 2.1 (1.1–3.7) 0.97
Deaths 2 (6.4) 12 (8.0) 1.00
Incidence rate, per 100 pt-years (95% CI) 1.4 (0.1–5.3) 2.0 (1.0–3.4) 0.64
Abbreviations: CI, confidence interval; BCS, Budd–Chiari syndrome; pt-years, patient years; SVT, splanchnic vein thrombosis.
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Figure 1. Thrombosis free-survival in patients with SVT index event
according to the type of first event (BCS; HR: 2.38, 95% CI: 1.08–5.38,
P= 0.02; upper panel) and history of remote thrombosis (HR: 2.57,
95% CI: 0.99–6.88, P= 0.04; lower panel).
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Figure 2. Thrombosis free-survival in patients with SVT index event
according to presence of splenomegaly (HR: 2.24, 95% CI: 1.00–6.71,
P= 0.05; upper panel) and the presence of leukocytosis at the
diagnosis (HR: 2.81, 95% CI: 1.17–6.34, P= 0.08; lower panel).
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thrombotic history8,9 and leukocytosis14,27,28 has been consistently
found in MPN patients, including both arterial and venous
thrombosis.
Interestingly, 38% of the patients had a blood cell count without
hypercythaemia, which is a finding quite common in MPN-related
SVT;25 moreover, no relevant leukopenia or thrombocytopenia
was recorded. Therefore, anticoagulation was considered safe and
was administered to 95% of patients, only a fraction of whom
(71%) received cytoreductive therapy; this practice was likely to be
due to the reluctance to use cytoreductive drugs in cases without
overt elevated blood counts. However, cytoreductive treatment
did not reduce the incidence rate of recurrent thrombotic events;
nevertheless, it should be highlighted that 17 of the 31 events
(55%) occurred in patients with hypercythaemia not receiving
cytoreduction or in patients who failed to reach the haematolo-
gical response in spite of cytoreduction.
Finally, splenomegaly emerged as an independent risk factor for
recurrent thrombosis in our series with SVT. This result is
consistent with other observations reporting a role of splenome-
galy for new episodes of thrombosis in patients without SVT as
well,29,30 even though this finding has not been confirmed by
other researchers.31 It has been speculated that splenomegaly
should be considered an index of more intensive myeloprolifera-
tion; however, its association with recurrent SVT may also be due
to a more extensive occlusion of the hepatic-portal venous axis. In
patients with SVT, the JAK2/JAK1 inhibitor Ruxolitinib has shown
significant activity in reducing the spleen volume,32 but no data
are available thus far on whether this finding is associated with
fewer recurrences. However, as reported in a recent meta-analysis,
there is evidence suggesting that the drug may reduce the rate of
total major thrombosis in myelofibrosis and PV.33 In our series only
four patients received ruxolitinib, so that no conclusion can be
drawn on this issue.
The incidence rate of recurrence in our patients was 3.9 per 100
pt-years in patients on VKA and 7.2 per 100 pt-years in patients off
VKA. This frequency is a new finding and agrees with other studies
of SVT in which the estimates were performed in the general
population with SVT, including only a minority of MPN. In these
reports, the frequency of recurrence ranged from 1.3 to 5.6 per
100 pt-years on VKA and from 3.3 to 11.9 per 100 pt-years after
VKA discontinuation.13,34–36 Notably, in patients with non-
splanchnic DVT on long-term treatment with VKA, the recurrence
rate is expected to be below 1 per 100 pt-years.37 The 2.0% rate of
major bleeding on VKA among our cases was similar to the rate in
SVT without MPN (from 1.2 to 3.9% pt-years)13,34–36 and was
slightly higher than expected in patients with non-splanchnic DVT
on long-term VKA treatment (0.9 per 100 pt-years).37 These
indirect comparisons suggest that in SVT, with or without MPN,
antithrombotic prophylaxis is associated with an inferior efficacy
and safety profile compared with other DVT cases. Therefore,
antithrombotic prophylaxis in SVT, particularly in BCS, is an unmet
clinical need and warrants prospective studies exploring the role
of new direct oral anticoagulants38 and the new JAK2 inhibitors in
MPN patients.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
TB and AMV were supported by a grant from Associazione Italiana per la Ricerca sul
Cancro (AIRC, Milano) ‘Special Program Molecular Clinical Oncology 5 × 1000’ to
AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative). VDS was supported by an
unrestricted grant from the Bruno Farmaceutici Foundation.
REFERENCES
1 De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk
factors and treatment. Intern Emerg Med 2010; 5: 487–494.
2 Rajani R, Melin T, Björnsson E, Broomé U, Sangfelt P, Danielsson A et al. Budd-
Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival—
an 18-year experience. Liver Int 2009; 29: 253–259.
3 Rajani R, Björnsson E, Bergquist A, Danielsson A, Gustavsson A, Grip O et al. The
epidemiology and clinical features of portal vein thrombosis: a multicentre study.
Aliment Pharmacol Ther 2010; 32: 1154–1162.
4 Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic
factors in mesenteric venous thrombosis. Br J Surg 2008; 95: 1245–1251.
5 De Stefano Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproli-
ferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb
Haemost 2016; 115: 240–249.
6 Martinelli I, De Stefano V, Carobbio A, Randi ML, Santarossa C, Rambaldi A et al.
Cerebral vein thrombosis in patients with Philadelphia-negative myeloprolifera-
tive neoplasms. An European LeukemiaNet study. Am J Hematol 2014; 89:
E200–E205.
7 Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproli-
ferative neoplasms. Br J Haematol 2013; 162: 730–747.
8 Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts
and management recommendations from European LeukemiaNet. J Clin Oncol
2011; 29: 761–770.
9 Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N et al.
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2015; 26(Suppl 5): v85–v99.
10 Ellis MH, Lavi N, Vannucchi A, Harrison C. Treatment of thromboembolic events
coincident with the diagnosis of myeloproliferative neoplasms: a
physician survey. Thromb Res 2014; 134: 251–254.
11 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neo-
plasms: the 2008 World Health Organization criteria and point-of-care diagnostic
algorithms. Leukemia 2008; 22: 14–22.
12 De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML et al.
High rate of recurrent venous thromboembolism in patients with myeloproli-
ferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia
2016; 30: 2032–2038.
13 Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M et al.
Long-term clinical outcomes of splanchnic vein thrombosis: results of an inter-
national registry. JAMA Intern Med 2015; 175: 1474–1480.
14 De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al. Recurrent
thrombosis in patients with polycythemia vera and essential thrombocythemia:
incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372–380.
15 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Sci-
entific and Standardization Committee of the International Society on Thrombosis
and Haemostasis. Definition of major bleeding in clinical investigations of anti-
hemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;
3: 692–694.
16 Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential
thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur
J Haematol 2006; 77: 327–333.
17 Amitrano L, Guardascione MA, Scaglione M, Pezzullo L, Sangiuliano N, Armellino MF
et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses.
Am J Gastroenterol 2007; 102: 2464–2470.
18 Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL et al.
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with
antithrombotic therapy based on the etiology. Transplantation 2011; 92: 341–345.
19 Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL. Long-
term follow-up of patients with portal vein thrombosis and myeloproliferative
neoplasms. J Thromb Haemost 2011; 9: 2208–2214.
20 Oldakowska-Jedynak U, Ziarkiewicz M, Ziarkiewicz-Wróblewska B, Dwilewicz-
Trojaczek J, Górnicka B, Nyckowski P et al. Myeloproliferative neoplasms and
recurrent thrombotic events in patients undergoing liver transplantation for
Budd-Chiari syndrome: a single-center experience. Ann Transplant 2014; 19:
591–597.
21 Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K et al. Long-term
outcome of liver transplant patients with Budd-Chiari syndrome secondary to
myeloproliferative neoplasms. Liver Int 2015; 35: 2042–2049.
22 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myelo-
proliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a
meta-analysis. Blood 2012; 120: 4921–4928.
23 Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in
patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010; 8:
200–205.
Splanchnic vein thrombosis in MPN
V De Stefano et al
6
Blood Cancer Journal
24 Søgaard KK, Farkas DK, Pedersen L, Sørensen HT. Splanchnic venous thrombosis is a
marker of cancer and a prognostic factor for cancer survival. Blood 2015; 126: 957–963.
25 Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S et al. The
impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein
thrombosis: a report on 241 cases. Blood 2008; 111: 4922–4929.
26 Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Asso-
ciation of V617F Jak2 mutation with the risk of thrombosis among patients with
essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
Thromb Res 2009; 124: 409–417.
27 Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al. Leu-
kocytosis as a major thrombotic risk factor in patients with Polycythemia Vera.
Blood 2007; 109: 2446–2452.
28 Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V et al.
Leukocytosis and risk stratification assessment in essential thrombocythemia.
J Clin Oncol 2008; 26: 2732–2736.
29 Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N et al. Bleeding,
thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis
from the German SAL-MPN-registry. J Hematol Oncol 2016; 9: 18.
30 Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A et al. Spleen
enlargement is a risk factor for thrombosis in essential thrombocythemia: eva-
luation on 1297 patients. Am J Hematol 2016; 91: 318–321.
31 Haider M, Gangat N, Hanson C, Tefferi A. Splenomegaly and thrombosis risk in essential
thrombocythemia: the Mayo Clinic experience. Am J Hematol 2016; 91: E296–E297.
32 Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M et al. Long term follow up of a
phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis asso-
ciated with myeloproliferative neoplasm. Blood 2015; 126: 2803 [abstract].
33 Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D. The
impact of ruxolitinib on thrombosis in patients with polycythemia vera and
myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis 2016; 27: 648–652.
34 Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R et al. Safety of vitamin K
antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study.
J Thromb Haemost 2015; 13: 1019–1027.
35 Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R et al. Recurrent thrombotic
events after discontinuation of vitamin K antagonist treatment for splanchnic vein
thrombosis: a multicenter retrospective cohort study. Gastroenterol Res Pract
2015; 2015: 620217.
36 Riva N, Ageno W, Schulman S, Beyer-Westendorf J, Duce R, Malato A et al. Clinical
history and antithrombotic treatment of incidentally detected splanchnic vein
thrombosis: a multicentre, international prospective registry. Lancet Hematol
2016; 3: e267–e275.
37 Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al. Com-
parison of low-intensity warfarin therapy with conventional-intensity warfarin
therapy for long-term prevention of recurrent venous thromboembolism. N Engl J
Med 2003; 349: 631–639.
38 Finazzi G, Ageno W. Direct oral anticoagulants in rare venous thrombosis. Intern
Emerg Med 2016; 11: 167–170.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2016
Splanchnic vein thrombosis in MPN
V De Stefano et al
7
Blood Cancer Journal
